215453-36-4

Upstream product

• 93-97-0 benzoic acid anhydride 
• 215453-35-3 thieno[3,2-c]pyridin-4-amine 
• 27685-92-3 thieno[3,2-c]pyridin-4-ol 
• 27685-94-5 4-chlorothieno[3,2-c]pyridine 

Downstream Products

• 215453-37-5 N-(2-formylthieno[3,2-c]pyridin-4-yI)benzamide 
• 215453-38-6 N-(2-hydroxymethyl-thieno[3,2-c]pyridin-4-yl)-benzamide 
• 215453-39-7 2-(4-benzoylamino-thieno[3,2-c]pyridin-2-ylmethyl)-2-tert-butoxycarbonylamino-malonic acid diethyl ester 

Relevant academic research and scientific papers

ENZYME INHIBITORS

The present invention provides compounds of formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, and, n, are as defined herein.

ENZYME INHIBITORS

The present invention provides compounds of formula (I) or (Ia) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, n, R2, R3, R4, R5, and R6 are as defined herein.

ENZYME INHIBITORS

The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, Y, n, R1, R2A, R2B, R3 and *1 are as defined herein.

Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors

Replacement of the highly basic benzamidine moiety with moderate basic amino-bicycloaryl moieties in a series of thrombin inhibitors related to NAPAMP provided potent enzyme inhibition and significant improvements in membrane transport and oral bioavailability.